RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating
加拿大皇家银行将神经分泌生物科学的目标股价从141美元下调至136美元，但保持板块表现评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册